Here we demonstrate not only the feasibility of establishing unique HER2+ and triple-negative immortalized primary breast cancer cell lines from their respective PDX tumors, but also draw genetic and drug phenotype comparisons between their respective organoid, PDX, and original patient primary tumor. This evidence concerns the gene ERBB2 and neoplasm.